Literature DB >> 33387335

Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease.

Mario Cozzolino1, Paola Ciceri2.   

Abstract

Entities:  

Year:  2021        PMID： 33387335     DOI： 10.1007/s40620-020-00885-z

Source DB:  PubMed          Journal:  J Nephrol        ISSN： 1121-8428            Impact factor:   3.902


× No keyword cloud information.
  9 in total

1.  Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.

Authors:  Steven Fishbane; Geoffrey A Block; Lisa Loram; John Neylan; Pablo E Pergola; Katrin Uhlig; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2017-01-12       Impact factor: 10.121

2.  Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.

Authors:  Wanghui Jing; Ane C F Nunes; Ted Farzaneh; Mahyar Khazaeli; Wei Ling Lau; Nosratola D Vaziri
Journal:  J Pharmacol Exp Ther       Date:  2018-08-09       Impact factor: 4.030

3.  Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Authors:  Sharon M Moe; Glenn M Chertow; Patrick S Parfrey; Yumi Kubo; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; David C Wheeler; Maria Stolina; Bastian Dehmel; William G Goodman; Jürgen Floege
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

4.  A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.

Authors:  Geoffrey A Block; Martha S Block; Gerard Smits; Rupal Mehta; Tamara Isakova; Myles Wolf; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2019-07-05       Impact factor: 10.121

5.  Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Authors:  Connor Francis; Guillaume Courbon; Claire Gerber; Samantha Neuburg; Xueyan Wang; Corey Dussold; Maralee Capella; Lixin Qi; Tamara Isakova; Rupal Mehta; Aline Martin; Myles Wolf; Valentin David
Journal:  Kidney Int       Date:  2019-08-30       Impact factor: 10.612

Review 6.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Authors:  Daniel Edmonston; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2019-09-13       Impact factor: 28.314

7.  Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).

Authors:  Megan L Noonan; Erica L Clinkenbeard; Pu Ni; Elizabeth A Swallow; Samantha P Tippen; Rafiou Agoro; Matthew R Allen; Kenneth E White
Journal:  Physiol Rep       Date:  2020-06

8.  Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis.

Authors:  Paola Ciceri; Monica Falleni; Delfina Tosi; Carla Martinelli; Stefania Cannizzo; Giulia Marchetti; Antonella D'Arminio Monforte; Gaetano Bulfamante; Geoffrey A Block; Piergiorgio Messa; Mario Cozzolino
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

9.  Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.

Authors:  Rebecca Womack; Fabian Berru; Bhupesh Panwar; Orlando M Gutiérrez
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-21       Impact factor: 8.237
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.